Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Somatostatin Receptor Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04888481
What this trial is testing

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Who this might be right for
Neuroendocrine Tumors
University of Alberta 600
Not applicableStudy completedNCT01879657
What this trial is testing

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Who this might be right for
Neuroendocrine Carcinoma
Radio Isotope Therapy of America 169
Early research (Phase 1)Looking for participantsNCT06441331
What this trial is testing

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Who this might be right for
Somatostatin Receptor PositiveNETsLymphoma+5 more
ITM Solucin GmbH 20
Not applicableLooking for participantsNCT04949282
What this trial is testing

Spanish Series of Patients Treated With the Radionuclide Lutetium177

Who this might be right for
Neuroendocrine TumorsIntestinal NeoplasmsPancreatic Neoplasms+15 more
Sociedad Española de Medicina Nuclear e Imagen Molecular 5,000
Testing effectiveness (Phase 2)Ended earlyNCT02177773
What this trial is testing

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

Who this might be right for
Neuroendocrine TumorParagangliomaCarcinoid Tumors+1 more
University of California, San Francisco 300
Not applicableStudy completedNCT05680675
What this trial is testing

Dual-Tracer Theranostic PET

Who this might be right for
Neuroendocrine TumorsProstate Cancer
University of Utah 50
Large-scale testing (Phase 3)Active Not RecruitingNCT05459844
What this trial is testing

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Who this might be right for
Neuroendocrine Tumors
Sinotau Pharmaceutical Group 196
Testing effectiveness (Phase 2)WithdrawnNCT04915144
What this trial is testing

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more
British Columbia Cancer Agency
Testing effectiveness (Phase 2)UnknownNCT05880394
What this trial is testing

Study of Dotatate Imaging in Breast Cancer

Who this might be right for
Breast Cancer Stage IV
Hoag Memorial Hospital Presbyterian 30
Large-scale testing (Phase 3)Active Not RecruitingNCT03049189
What this trial is testing

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 324
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Temporarily pausedNCT01876771
What this trial is testing

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Who this might be right for
Carcinoma, Neuroendocrine
AHS Cancer Control Alberta 413
Testing effectiveness (Phase 2)Looking for participantsNCT04665739
What this trial is testing

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Who this might be right for
Advanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine TumorLocally Advanced Lung Neuroendocrine Neoplasm+9 more
National Cancer Institute (NCI) 70
Post-approval studies (Phase 4)Looking for participantsNCT04081701
What this trial is testing

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

Who this might be right for
CNS TumorsMeningiomaEsthesioneuroblastoma+4 more
Weill Medical College of Cornell University 200
Early research (Phase 1)Looking for participantsNCT05687123
What this trial is testing

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Who this might be right for
Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more
National Cancer Institute (NCI) 24
Not applicableActive Not RecruitingNCT03691064
What this trial is testing

Post-Authorization Long-Term Safety Study of LUTATHERA

Who this might be right for
Neuroendocrine Tumors
Advanced Accelerator Applications 1,014
Testing effectiveness (Phase 2)UnknownNCT02236910
What this trial is testing

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours

Who this might be right for
Neuroendocrine Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 66
Testing effectiveness (Phase 2)Looking for participantsNCT06045260
What this trial is testing

"Receptor Radionuclide Therapy With 177Lu-DOTATOC

Who this might be right for
Neuroendocrine TumorsParagangliomaPheochromocytoma
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 100
Early research (Phase 1)Active Not RecruitingNCT04609592
What this trial is testing

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Stanford University 10